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Recurrent pregnancy loss 
Recurrent miscarriage 
A B S T R A C T   
Many cases of recurrent pregnancy loss (RPL) defined as ≥3 consecutive pregnancy losses are suggested to be 
caused by an aberrant maternal immune response against the fetus or trophoblast. Human leukocyte antigen 
(HLA)–DRB1 and -DQB1 polymorphisms are associated with most autoimmune disorders and studies of HLA- 
DBB1 polymorphism in RPL patients are thus relevant. In previous studies, the HLA-DRB1*03 allele was 
found with increased prevalence in RPL patients. 
We wanted to clarify whether HLA-DRB1 alleles indeed were associated with RPL among women of Caucasian 
descent. A total of 1078 women with unexplained RPL and 2066 bone marrow donors were HLA-DRB1-typed and 
subsets were also HLA-DQB1 typed. 
All patients were initially HLA-DRB1-typed by DNA-based low-resolution techniques and subsets of patients 
and all controls were typed by high-resolution techniques. 
Among patients, the HLA-DRB1*07 allele frequency was significantly increased compared with controls; OR 
1.29 (95 % CI 1.09− 1.52), p < 0.0025; after correction for multiple comparisons pc = 0.031. The HLA-DRB1*07/ 
*07 genotype was highly increased in patients with RPL compared with controls: OR 2.27 (1.31− 3.93), p =
0.0027. The frequency of the HLA-DRB1*07 phenotype in RPL patients had increased significantly (p = 0.002) in 
three studies from our group published 1994–2021. The allele frequency of HLA-DRB1*03 was not increased in 
RPL patients compared with controls; OR 0.96 (0.83− 1.12). 
In conclusion, the previous association between HLA-DRB1*03 and RPL could not be confirmed in our study 
whereas an association to HLA-DRB1*07 was detected for the first time. Since the latter association is a new 
finding, it should be confirmed in future studies.   
1. Introduction 
The HLA region comprises several genetic loci located on chromo-
some 6p21.31 and it contains the most polymorphic genes known in 
humans. Genes in most HLA loci are involved in interactions in the 
immune system through various mechanisms. So called classical HLA 
class I genes (HLA-A, -B and C) play important roles in transplantation 
immunology. In addition, class I HLA molecules seem to play a role in 
immune interactions of importance to pregnancy. Fetal HLA-C can 
interact with maternal natural killer (NK) cell receptors that may 
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influence the risk of pregnancy loss (Hiby et al., 2008). The non-classical 
HLA-class Ib gene HLA-G probably plays an important role in human 
reproduction since it is strongly expressed on extravillous trophoblast, 
which is in close contact with the maternal immune system and almost 
devoid of other HLA molecules. Polymorphisms in the HLA-G gene that 
may affect gene expression seem to play a role in several pregnancy 
complications such as recurrent pregnancy loss (RPL) (Hviid et al., 2002; 
Wang et al., 2013; Fan et al., 2014) and low birthweight (Emmery et al., 
2017). 
The clinically most important HLA class II loci are HLA-DRB1, -DQA1 
and -DQB1. Genes in these loci code for glycoprotein molecules consti-
tutively expressed on the surface of B-lymphocytes and dendritic cells. 
Class II molecules on the surface of these cells present peptides derived 
from exogenous proteins (e.g. bacteria) to receptors on T-helper cells. 
The T cells then initiate a cellular and humoral immune response against 
the peptide. 
The two sets of HLA genes carried by every individual are strong 
determinants of the repertoire of proteins against which the individual 
can mount immunological responses. The repertoire of autologous HLA 
molecules is also important for the development and specificity of a 
subpopulation of T regulatory (Treg) cells, which can suppress autor-
eactive T cells that have escaped negative selection in the thymus. Treg 
populations and thus autologous major histocompatibility (MHC) 
polymorphism seems to be important for immunological tolerance to 
pregnancy both in mice (Aluvihare et al., 2004; Darrasse-Jeze et al., 
2006) and humans (Jin et al., 2009; Kwiatek et al., 2015). 
There are many indications that RPL defined as ≥ 3 consecutive 
pregnancy losses (miscarriages and biochemical pregnancy losses) 
before gestational week 20 (Jauniaux et al., 2006) is associated with 
aberrant immune function and in particular breakage of immunological 
autotolerance and autoimmunity. Several autoantibodies such as anti-
phospholipid, antinuclear and thyroid peroxidase (TPO) antibodies can 
be detected with increased prevalence in these women (Christiansen 
et al., 1998; Ticconi et al., 2010; van den Boogaard et al., 2011) and are 
associated with prognosis (Bliddal et al., 2019). In addition, most clin-
ical autoimmune diseases are more common in RPL patients than in the 
background population (Christiansen et al., 2008). In follow-up studies, 
atherosclerotic diseases with a possible background in an increased in-
flammatory state develop more often than expected in patients with a 
diagnosis of RPL or late pregnancy loss (Ranthe et al., 2013; Kessous 
et al., 2014; Egerup et al., 2020; Westergaard et al., 2020). Most disor-
ders associated with autoimmunity are associated with HLA class II 
polymorphisms (Viatte et al., 2015) and therefore it is of interest to 
investigate the role of HLA class II in women with RPL. 
In the largest case-control study so far of 588 Caucasian RPL patients 
and 562 Caucasian controls, the HLA-DRB1*03 allele was found with 
significantly increased prevalence in patients also after correction for 
multiple comparisons (Kruse et al., 2004). The association to 
HLA-DRB1*03 was stronger in patients with ≥ 4 previous pregnancy 
losses and in patients with RPL after a birth (secondary RPL). 
In prospective studies we have reported that HLA class II alleles 
associated with immunity against male specific minor histocompatibil-
ity (HY) antigens, primarily HLA-DRB1*15, -DRB1*07 and 
-DQB1*0501/0502 exhibited a negative prognostic impact in patients 
with RPL after the birth of a boy (Nielsen et al., 2009; Kolte et al., 2016). 
Furthermore, maternal carriage of HLA-DRB1*03 and HLA-DRB1*01 
(the latter in strong positive linkage disequilibrium with 
HLA-DQB1*0501/*0502) were previously reported to be associated 
with a significantly reduced pregnancy prognosis in all RPL patients 
(Christiansen et al., 1993). The topic of HLA-DRB1 polymorphisms and 
RPL is controversial: in a systematic review and meta-analysis of 8 
case-control studies, HLA-DRB1*04 and HLA-DRB1*15 were found to 
confer susceptibility to RPL whereas HLA-DRB1*03 was only borderline 
associated (Meuleman et al., 2015). However, only three of the studies 
were performed in Caucasians. In the study of Meuleman et al. (2015) a 
meta-analysis of studies of HLA sharing (also called HLA matching) was 
also performed. In matching studies, instead of comparing the frequency 
of HLA alleles in women with RPL with that in controls, the frequency of 
sharing 0, 1 or 2 alleles in different loci between women with RPL and 
their husbands (as a proxy for feto-maternal HLA sharing) is compared 
with the sharing rate in control couples. In the meta-analysis of Meu-
leman et al. (2015) significantly increased sharing of HLA-B and 
HLA-DR alleles was found in RPL couples. Increased HLA allele match-
ing between women with RPL and their fetuses have been suggested to 
result in decreased immunological allorecognition of paternal antigens 
in the fetus that may increase the miscarriage risk. 
In order to clarify the question whether particular HLA-DRB1 alleles 
are associated with RPL we undertook the present study, which is sub-
stantially larger than previous studies on the topic. We tested the hy-
pothesis that HLA-DRB1*03 is significantly associated with RPL, and, in 
addition we investigated if there are other HLA-DRB1 alleles predis-
posing to or protecting against RPL. 
2. Materials and methods 
2.1. Patients 
Between 2003 and 2016, 1778 women were referred to the national 
RPL clinic in Copenhagen from all over Denmark. In principle, patients 
needed to fulfill the criteria of three or more consecutive pregnancy 
losses. At referral, comprehensive information about the patients’ 
reproductive history, previous investigations and treatments, menstrual 
cycle and ancestry (country of origin) were entered into a database 
(Danish Data Protection Agency approval numbers 2009-41-3686/ 
2012-58-0004). Blood samples were routinely taken from all patients 
for HLA-DRB1 typing by low-resolution and excess DNA storage. High- 
resolution HLA-DRB1 typing and HLA-DQA1 and -DQB1 typing was 
undertaken in HLA-DRB1*07 positive patients. 
In this study, we excluded a total of 700 patients due to various 
causes (Fig. 1). We aimed to only include women of Caucasian ethnicity. 
Women with origin from Asia (except Russia) and Africa and women of 
Afro-American ancestry from Europe and North and South America were 
excluded. Menstrual disturbances were defined as the majority of cycles 
<21 or >35 days within the last year before referral. Additional exclu-
sion criteria were significant chromosomal abnormalities (primarily 
balanced translocations) in any of the parents and significant uterine 
malformations (septum or bicornuate uterus) or fibromas detected at 
hysteroscopy or hysterosalpingography. Women with exclusively 
biochemical pregnancies were also excluded since we believe that a 
substantial part of these women had experienced recurrent spontane-
ously resorbed ectopic pregnancies rather than recurrent intrauterine 
pregnancy losses (Kolte et al., 2014). A total of 1078 patients ended up 
being eligible for the study and had been HLA-DRB1 typed or had DNA 
stored for typing. 
The mean age of the women was 34.08 years (SD 4.93; range 21–45) 
and the mean number of pregnancy losses among all the included 
women was 4.06 (SD 1.38; range 3–12). 
Patients with autoantibodies and heritable thrombophilia factors 
were not excluded. There is an association between particular HLA- 
DRB1 alleles and autoantibody production (e.g. anticardiolipin and 
HLA-DRB1*03; Christiansen et al., 1998) and one of the causal links 
between HLA and autoimmune disease may be autoantibody production 
associated with the susceptibility HLA alleles. Excluding autoantibody 
positive patients will probably confound the results. 
The only autoantibodies that have been consistently tested in our 
patients referred since 2011 are the antiphospholipid antibodies lupus 
anticoagulant and anticardiolipin and TPO antibodies. The frequency of 
positivity for TPO antibodies (> 60 kIU/l) in 825 consecutive patients 
was 16.8 % and the frequency of the antiphospholipid syndrome in 511 
patients who became pregnant 2011− 17 was 3.5 % (Bliddal et al., 
2018). In the period 2003–2007, 1.2 % of our patients had a diagnosis of 
systemic lupus erythematosus, 4.5 % had hyper- or hypothyreosis, 1.2 % 
C.K. Thomsen et al.                                                                                                                                                                                                                            
Journal of Reproductive Immunology 145 (2021) 103308
3
had type 1 diabetes mellitus and 1.5 % had inflammatory bowel disease 
(Christiansen et al., 2008). 
With regard to thrombophilia factors such as the factor II and V gene 
variants, Protein S and C deficiency and hyperhomocysteinaemia, the 
ESHRE Guideline Recurrent Pregnancy Loss (ESHRE Guideline Group on 
RPL, 2018) suggests not to screen for hereditary thrombophilia in RPL 
patients since there is insufficient evidence that these factors cause RPL 
and no proven treatment exists. Until more is known about the impact of 
hereditary thrombophilia in RPL it would be wrong to select patients 
based on positivity or negativity for these factors to studies of other 
potential risk factors in RPL. 
2.2. Controls 
The control group comprised 2066 healthy individuals from the 
Danish registry of bone marrow donors (BMD), who had been HLA class 
II typed with high resolution at 4-digit allelic level when they vol-
unteered for the registry. The criterion for being included in this registry 
was absence of known disease. The only information available regarding 
this group was surname, sex and age. After checking names, one indi-
vidual with an Indian name was excluded whereas the other names 
suggested Danish ancestry. Of the controls, 56.34 % were women and 
their mean age was 36.74 year, (SD 9.20, range 18–64). 
Since the control persons were anonymous and no extra blood 
samples were taken or extra analyses were performed, no consent is 
needed for including the controls according to the Standards of Trans-
fusion Medicine published by the Danish Society of Clinical Immunology 
(Transfusionsmedicinske Standarder. Version 5.1, 2020). 
2.3. HLA-typing methodology 
2.3.1. DNA preparation 
DNA from EDTA-treated peripheral blood was extracted either using 
a salting-out method as previously described (Miller et al., 1988) or 
using the Maxwell 16 Blood DNA kit on the Maxwell 16 Instrument. DNA 
from buccal swabs were extracted using Maxwell 16 Buccal Swab LEV 
DNA Purification Kit on the Maxwell 16 Instrument (Promega, Madison, 
WI, USA). 
2.3.2. HLA typing with low-resolution 
HLA-DRB1 typing was performed using the Luminex xMAP system 
LABType SSO, a reverse SSO DNA typing system (One Lambda Inc., 
Canoga Park, CA, USA) according to the manufacturer’s instructions. 
2.3.3. HLA-DRB1 and DQB1 typing with high resolution 
Next generation sequencing (NGS)-based HLA typing using the Illu-
mina MiSeq platform was performed at Histogenetics (NY, USA). HLA 
typing with 2x high resolution at 4-digit allelic level without ambiguities 
for HLA-DRB1 and HLA-DQB1 was used for large-scale HLA class II 
genotyping. Exon 2 and 3 were sequenced for HLA class II alleles. 
2.3.4. Allele frequency versus phenotype frequencies 
In the primary analysis we report the allele frequencies, which is the 
frequency of a specific HLA allele among all alleles in the locus; there-
fore, the number in the denominator is 2 x the number of individuals. 
The allele frequency is the most commonly used unit in HLA studies 
since it does not implicate a dominant mode of action of the disease 
susceptibility alleles and with modern techniques both alleles in the loci 
can be unambiguously determined. 
“Phenotype frequency” is the frequency of individuals carrying a 
specific allele. We primarily present phenotype frequencies when our 
results are analyzed in a context with those of previous publications 
where phenotype frequencies were the unit of measure. 
2.4. Statistics 
All data were entered in an Access database and calculations were 
primarily done in Excel. Allele and phenotype frequencies were 
compared with χ2 test or Fisher’s exact test where appropriate due to 
small numbers. For each table of allele comparisons, p-values were 
Fig. 1. Flow-chart showing causes of exclusion and numbers of excluded recurrent pregnancy loss patients in the study.  
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corrected by the Bonferroni method by multiplication with the number 
of alleles tested except for HLA-DRB1*03, which was a-priori considered 
a susceptibility allele for RPL. ORs and their 95 % CIs were calculated for 
each comparison of allele or genotype frequencies. Trends in change in 
≥3 frequencies were statistically evaluated by Mantel-Haenzel χ2 test 
for trend. Population attributable risks (PAR) were calculated by the 
formula: PAR = Pe (ORe – 1)/1+ Pe (ORe -1), where Pe is the prevalence 
of the exposure in the background population and ORe is the risk of the 
disease in exposed individuals. A p-value < 0.05 was considered 
significant. 
3. Results 
3.1. Allele frequencies in patients and controls 
The allele frequency of HLA-DRB1*03 was not increased in RPL 
patients compared with the control group, OR 0.96 (95 % CI 0.83− 1.12) 
(Table 1). 
The HLA-DRB1*07 allele frequency was significantly increased 
compared with controls; OR 1.29 (95 % CI 1.09− 1.52), p < 0.0025; after 
adjusting for multiple comparisons pc = 0.031. 
In controls, we found no significant differences in the allele fre-
quencies between the two sexes (HLA-DRB1*03: 13.6 % and 14.1 % in 
females and males, respectively and HLA-DRB1*07: 10.3 % and 9.1 % in 
females and males, respectively. ORs for RPL for the two alleles remain 
almost the same (HLA-DRB1*03: OR 1.00; 95 % CI 0.84–1.19 and HLA- 
DRB1*07: OR 1.22; 95 % CI 1.01− 1,47), p < 0.05) if comparisons were 
done to only female controls. 
The frequencies of all other broad HLA-DRB1 alleles were strikingly 
similar between RPL patients and controls (Table 1). 
3.2. Phenotype frequencies in subsets of patients 
The frequency of the HLA-DRB1*03 phenotype was not different 
between patients with primary or secondary RPL but tended to increase 
(p = 0.09) with the number of previous pregnancy losses (Table 2). The 
frequency of the HLA-DRB1*07 phenotype did not differ significantly 
between RPL patients with primary and secondary RPL or 3 or ≥ 4 
previous pregnancy losses (Table 2). The PAR for RPL associated with 
HLA-DRB1*07 was 0.044. 
3.3. HLA-DRB1*07 haplotypes in patients and controls 
Table 3 depicts the distribution of the two different HLA-DRB1-DQB1 
haplotypes carrying HLA-DRB1*07 alleles in RPL patients and the con-
trol group. Differences in distribution of the HLA-DRB1*07-DQB1*02 
and DRB1*07-DQB1*03 haplotypes between patients and controls was 
not statistically significant. 
3.4. HLA-DRB1 genotypes in patients and controls 
In Table 4 are shown the frequencies in RPL patients and the control 
group of three HLA-DRB1 genotypes including the two alleles exhibiting 
significantly different frequencies in patients and controls in our previ-
ous and present studies. Homozygosity for HLA-DRB1*07 was found 
significantly more often in RPL patients compared with controls (OR =
2.27; 95 % CI 1.31− 3.93, p = 0.0027). The other genotypes did not 
differ significantly between patients and controls. 
3.5. HLA-DR3 and HLA-DR7 and RPL in historical context 
Table 5 shows data from two previous publications from the Danish 
RPL clinics in addition to data from the present study on the frequency of 
RPL patients and controls being positive for the two HLA-DRB1 alleles of 
particular interest in this study: HLA-DRB1*03 and -DRB1*07. The fre-
quency of the HLA-DRB1*07 phenotype in RPL patients has increased 
significantly from 1994 to 2021 (p = 0.002) whereas the change in the 
HLA-DRB1*03 phenotype frequency in patients was not significant (p =
0.20). 
The frequency of the HLA-DRB1*03 phenotype has exhibited 
considerable variability in controls during the years (Table 5). In 
contrast, the frequency of the HLA-DRB1*07 phenotype has stayed 
stable over the years in the control populations. 
3.6. Non-visualized pregnancy losses in HLA-DRB1*03 and -DRB1*07 
homozygous patients 
When reviewing the reproductive history in HLA-DRB1*03 homo-
zygous patients, 29 (44.6 %) of 65 pregnancy losses could be classified as 
non-visualized pregnancy losses (biochemical pregnancies and 
Table 1 
Frequencies of HLA-DRB1 alleles in recurrent pregnancy loss (RPL) patients and 







OR (95 % CI) P; Pc 
01 10.76 11.08 0.97 
(0.82− 1.14) 
0.7 
03 13.08 13.53 0.96 
(0.83− 1.12) 
0.6 
04 17.16 16.36 1.06 
(0.92− 1.22) 
0.4 




08 3.15 3.75 0.84 
(0.63− 1.12) 
0.2 
09 1.07 0.85 1.26 
(0.74− 2.14) 
0.4 
10 0.70 0.56 1.25 
(0.65− 2.40) 
0.5 
11 7.42 6.97 1.07 
(0.88− 1.31) 
0.5 
12 2.46 2.54 0.97 
(0.69− 1.35) 
0.8 
13 12.76 13.75 0.92 
(0.79− 1.07) 
0.3 
14 2.27 2.23 1.02 
(0.72− 1.45) 
0.9 
15 16.14 17.52 0.91 
(0.79− 1.40) 
0.2 
16 0.83 1.06 0.78 
(0.45− 1.36) 
0.4 
Pc: p-values adjusted for number of comparisons (n = 13). 
Table 2 
Frequencies of selected HLA-DRB1 phenotypes in subsets of recurrent pregnancy 












≥ 4 pregnancy 
losses (n = 599) 
DRB1*03 23.4 24.6 22.1b 26.6b 
DRB1*07 22.7 21.1 22.5 21.6  
a Some patients could not be classified in either subgroup. 
b p = 0.09. 
Table 3 
Distribution of HLA-DRB1*07 positive haplotypes in recurrent pregnancy loss 
(RPL) patients and blood marrow donor controls.  











29.0 % 34.6 %  
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pregnancies of unknown location = PULs). In HLA-DRB1*07 homozy-
gous patients, 35 out of 103 (34.0 %) of the pregnancy losses were non- 
visualized losses. 
4. Discussion 
The present study is by far the largest case-control study of HLA- 
DRB1 prevalence in patients with RPL and relevant controls and all 
HLA typings were done with up-to-date DNA based techniques, which 
will detect all broad HLA-DRB1 alleles in an individual in contrast to 
older techniques based on serology. 
Surprisingly, when compared with the control group there was no 
difference in the HLA-DRB1*03 frequency in RPL patients. 
In studies of genetic biomarkers in patients with a specific disease 
and controls, it is a matter of controversy, which is the optimal control 
group: individuals without the disease (e.g. a group of women with 
children and no pregnancy losses) or individuals selected randomly from 
the population? The control group of bone marrow donors was selected 
due to absence of disease (including autoimmune diseases), which may 
affect the HLA-DRB1 allele distribution in an unpredictable way. 
A surprising finding in this study was that HLA-DRB1*07 was 
increased in the RPL group compared with controls, and this result was 
highly significant (p < 0.0025). In our previous case-control studies 
there was no indication that this allele confers susceptibility to RPL since 
OR for RPL was 0.9 in both studies (Christiansen et al., 1994; Kruse et al., 
2004). However, the low p-value, which survives Bonferroni correction 
strengthens the belief that the association is real. 
The question is why HLA-DRB1*07 has not been associated with RPL 
in previous studies? It is possible that previous estimates have been 
imprecise due to smaller numbers. However, Table 5 shows that the 
phenotype frequencies of HLA-DRB1*07 in RPL patients have increased 
significantly (p = 0.002) and stepwise from 14.1% to 22.0% in our three 
studies published from 1994 until now. In comparison, the corre-
sponding frequencies of HLA-DRB1*03 have remained stable over the 
years in both the control groups of fertile women and blood and bone- 
marrow donors. Although the technique in our laboratory for DNA- 
based detection of HLA-DR polymorphisms has changed from the 
restriction fragment length polymorphism method (Erlich et al., 1986) 
to a number of polymerase chain reaction (PCR) methods (Fernandez--
Vina et al., 1991), oligonucleotide probe hybridization (Saiki et al., 
1986) and direct sequencing of amplification products (Gyllensten and 
Erlich, 1988), the stable HLA-DRB1*07 frequencies in all control groups 
suggest that changed techniques are not responsible for the increased 
DRB1*07 frequency in patients. 
The increase of DRB1*07 frequency in RPL over the past 30 years 
may instead be explained by changes in the constitution of the patient 
population and its exposure to risk factors for RPL. Compared with the 
period before 2000, the patient population now comprises more patients 
with non-visualized pregnancy losses only detected by high-sensitive 
plasma hCG test, which only became generally available after 2000. 
However, among HLA-DRB1*07 homozygous RPL patients, the fre-
quency of non-visualized pregnancy losses was similar to that in our 
total patient group previously published by Kolte et al. (2014), 34.0 % 
versus 37.8 %. Therefore, inclusion of non-visualized losses in the RPL 
diagnosis does not fully explain the increase in HLA-DRB1*07. Another 
factor that has changed significantly over the years is female age. The 
RPL patients have become older from 1994 to now. Egerup et al. (2016) 
reported a mean age of 32.5 years before 1994 and 34.4 years after 2008 
in secondary RPL patients participating in randomized controlled trials. 
Increased mean age is expected to increase the frequency of patients 
getting the RPL diagnosis due to recurrent aneuploid conceptions and 
this may explain the weakened association between RPL and 
HLA-DRB1*03 but cannot explain the new association with 
HLA-DRB1*07. Other examples of changes in HLA associations with 
autoimmune disease over time have been reported. The frequencies of 
HLA-DRB1 alleles and genotypes providing susceptibility to type 1 
diabetes were significantly lower in patients diagnosed between 1985 
and 2002 compared with patients diagnosed in previous years (Hermann 
et al., 2003; Gillespie et al., 2004). An explanation could be that a 
temporal increase in environmental risk factors for type 1 diabetes have 
weakened the proportion of the cases caused by HLA-DRB1 alleles 
conferring susceptibility to type 1 diabetes. In RPL, it is possible that 
changes in vaginal/uterine microbiomas or endocrine disruptors in the 
environment over time have promoted the development of new epitopes 
on the fetal or trophoblast cells that are targets for HLA-DRB1*07 
restricted T-helper cells. 
It can be questioned whether the control group includes non- 
Caucasians since only one donor of presumed non-Caucasian origin 
was excluded from the control group whereas 11.2 % of the patients 
were excluded due to non-Caucasian ethnicity. There is no official 
registration of the ethnic origin of Danish blood donors, but in the 
newsletter of the organization of Danish blood donors (Bloddonor no. 
119, autumn 2016) it is estimated that only 2% of Danish blood donors 
are of non-Danish ancestry and the frequency of non-Caucasian blood 
and bone-marrow donors is probably substantially lower. The vast ma-
jority of citizens in Denmark of non-Caucasian ancestry comes from the 
Middle East and Turkey. In these counties the HLA-DRB1*15 allele is 
relatively rare comprising 3.6–9.0 % in Eastern Mediterranean Arabs 
(Hajjej et al., 2018) and 7.5–8.0 % in Turks (Patiroglu and Akar, 2016; 
Esendagli et al., 2018). The HLA-DRB1*15 allele frequency of 17.52 % in 
our control group is very similar to the corresponding frequency of 
16.72 % among 4514 Caucasian bone-marrow donors in Norway (Lande 
et al., 2018) suggesting a very low admixture of individuals with Arab 
and Turkish ancestry in our control group. The distribution of other 
HLA-DRB1 alleles between our controls and the Norwegian donor group 
is also very similar. 
If both HLA-DRB1*03 (previous studies) and HLA-DRB1*07 (present 
study) indeed are associated with RPL, which is a situation very similar to 
celiac disease (Spurkland et al., 1997; Donat et al., 2009) the question is 
whether similar disease mechanisms lay behind the two conditions. In Cau-
casians, HLA-DRB1*03 is usually found on the very conserved 
HLA-DRB1*03-DQA1*05-DQB1*02 haplotype. In contrast, HLA-DRB1*07 is 
found on either the HLA-DRB1*07-DQA1*03-DQB1*03 or the 
Table 4 
Frequencies of genotypes including HLA-DRB1*03 and -DRB1*07 in recurrent 
pregnancy loss (RPL) patients and blood marrow donor controls.  
DRB1 
genotype 
% RPL (n =
1078) 
% Controls (n =
2066) 
OR (95 % CI) P 
03/03 1.58 2.18 0.72 
(0.41− 1.26) 
0.25 
07/07 2.60 1.16 2.27 
(1.31− 3.93) 
0.0027 




Frequency of selected HLA-DR phenotypes in recurrent pregnancy loss (RPL) 
patients and fertile controls and blood or bone marrow donors in three Danish 
case-control studies.   
HLA-DR3 % HLA-DR7 % 
RPL 1994a (n = 234) 28.2d 14.1e 
RPL 2004b (n = 354) 26.6d 16.9e 
RPL 2021c (n = 1078) 24.6d 22.0e 
Fertile controls 2004b (n = 202) 20.8 17.8 
Donor controls 1994a (n = 360) 21.1 17.5 
Donor controls 2021c (n = 2066) 24.9 18.4  
a Christiansen et al. (1994). 
b Kruse et al. (2004). 
c This study. 
d p = 0.20. 
e p = 0.0022. 
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HLA-DRB1*07-DQA1*02-DQB1*02 haplotype. In celiac disease, it was found 
that carriers of the HLA-DRB1*03-DQA1*05-DQB1*02 haplotype or the 
HLA-DRB1*11(12)-DQA1*05-DQB1*03/DRB1*07-DQA1*02-DQB1*02 ge-
notype had the highest risk of disease because these haplotypes/genotypes 
could form a HLA-DQ α1*05, β1*02 heterodimeric molecule which has been 
documented to present gliadin-derived peptides with high affinity to T-cells, 
which can result in celiac disease. 
In Table 3 we investigated whether the HLA-DRB1*07-DQB1*02 
haplotypes were over-represented among the HLA-DRB1*07 positive 
haplotypes in RPL patients compared with the control group; however, 
this was not the case. We therefore conclude that the molecular back-
ground for the possible association between HLA-DRB1*03 and HLA- 
DRB1*07 and RPL is not similar to that found in celiac disease: forma-
tion of a heterodimer between specific DQ α1 and β1 chains. 
The OR for RPL in carriers of the DRB1*07 allele is modest: 1.29 and 
is so far of limited value when advising patients about causes and risk for 
RPL. The clinical impact must be clarified in future prospective studies. 
However, previous studies have provided some preliminary documen-
tation that HLA-DRB1*07 affects the pregnancy prognosis negatively in 
women with secondary RPL after a boy (Kolte et al., 2016) but larger 
prospective studies are needed. 
The PAR of the HLA-DRB1*07 allele was 0.044. This can be inter-
preted as if this HLA-DRB1 allele disappeared from the population 4.4 % 
of all RPL cases would disappear. This fraction of the RPL cases that can 
possibly be explained by HLA-DRB1 related factors should not be 
ignored. 
The HLA-DRB1*07/*07 genotype was highly significantly increased 
(OR 2.27) in RPL patients compared with controls. If the higher geno-
type OR (relative to the phenotype OR of 1.29) for RPL is confirmed in a 
new study, this points towards a synergistic or additive effect of the two 
alleles carried by a woman, which can provide clues about the patho-
physiological mechanisms. 
What can be the pathophysiologic link between the HLA-DRB1*07 
allele and RPL? It has been reported that HLA-DRB1*07 can restrict 
presentation of specific male-specific HY antigens to T-lymphocytes 
(Eljaafari et al., 2013) in vitro and it seems that women with secondary 
RPL, who delivered a boy before the series of pregnancy losses, the 
pregnancy prognosis is reduced if they are carriers of HLA-DRB1*07 
(Kolte et al., 2016). HY proteins are strongly expressed on the tropho-
blast, which can thus be a target for harmful maternal immune reactions 
in HLA-DRB1*07 positive mothers. In the present study we did not find 
the HLA-DRB1*07 with higher frequency in secondary than in primary 
RPL (Table 2), which is an argument against an anti-HY pathogenesis. 
In conclusion, in this large case-control study we have found strong 
evidence that HLA-DRB1*07 confers susceptibility to RPL in Caucasians. 
The study should be repeated in a new group of patients. In addition, 
prospective studies should clarify whether carriage of HLA-DRB1*07 
impacts future pregnancy outcome in women with RPL after adjust-
ment for confounders. If a negative prognostic impact is confirmed, 
HLA-DRB1 testing could be a part of the RPL screening programme. 
Furthermore, laboratory studies should clarify, which peptides derived 
from trophoblast/fetal proteins can be presented by antigen-presenting 
cells from HLA-DRB1*07 positive individuals to T-helper lymphocytes 
and initiate a cellular and humoral immune response. Such knowledge 
could be very helpful in the development of immunomodulatory 
interventions. 
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